Coronado Industries Issues Update On PNT Initiatives.Business Editors/Health & Medical Writers FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--Aug. 7, 2000 Coronado Industries, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CDIK), a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, announced today that it is moving steadily towards FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval and distribution of its pneumatic trabeculoplasty (PNT PNT Point PNT Paint (MacPaint graphic file format) PNT Patient PNT Pentagon (Washington, DC; US DoD) PNT Positioning, Navigation and Timing PNT Prime Number Theorem PNT Phenytoin (TM)) glaucoma treatment. Coronado President Gary R. Smith commented, "Although we have not yet reached closure, we are completely on track, and our prospects, both for FDA approval and possible distribution commitments, look very bright." Coronado Industries, through its wholly-owned subsidiaries American Glaucoma and Ophthalmic International, focuses on the development and testing of a patented procedure, Pneumatic Trabeculoplasty (PNT), a non-invasive, highly effective, and low-cost alternative to traditional treatments. Coronado Industries' PNT treatment is designed to treat the two most common types of glaucoma - open-angle and pigmentary glaucoma. A suction device, applied to the eye for two minutes, reduces intraocular pressure intraocular pressure n. The pressure of the intraocular fluid within the eye. intraocular pressure (in´tr non-invasively. After four years' evaluation of PNT/glaucoma trial results, the treatment has been proven to offer some value in the treatment of ocular hypertension as well. Forward-looking statements in this release are made pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion